Danish pharmaceutical manufacturer Novo Nordisk recently achieved a market valuation of roughly $500 billion, making it only the second European company to ever break that half-trillion-dollar market cap barrier—and also making its value larger than the GDP of Denmark, the country where it’s based. Novo Nordisk’s explosive growth has been driven by its manufacturing of diabetes and anti-obesity drugs, including Ozempic, which have seen surging demand around the world—and resulted in an influx of money into Denmark.

QOSHE - How Weight-Loss Drugs Are Distorting the Danish Economy - Cameron Abadi, Adam Tooze
menu_open
Columnists Actual . Favourites . Archive
We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

How Weight-Loss Drugs Are Distorting the Danish Economy

5 0
02.02.2024

Danish pharmaceutical manufacturer Novo Nordisk recently achieved a market valuation of roughly $500 billion, making it........

© Foreign Policy

Get it on Google Play